Core Viewpoint - Lu Kang Pharmaceutical (600789.SH) and its subsidiary, Shandong Lukang Pharmaceutical Group Saiter Co., Ltd., have successfully won bids for several drugs in the recent centralized procurement process, indicating a positive development for the company's market position and revenue potential [1] Group 1 - The selected products include: injectable cefazolin sodium, dapagliflozin tablets, adenosylcobalamin capsules, and mesobalamin injection [1] - The total sales revenue for the selected products in 2024 is projected to be 405 million yuan [1]

Core Viewpoint - LuKang Pharmaceutical (600789.SH) and its subsidiary, Shandong Lukang Pharmaceutical Group Sait Company, have successfully won bids for several drugs in the recent centralized procurement process, indicating a positive development for the company's market position and revenue potential [1] Group 1 - The selected products include: Cefoperazone Sodium for Injection, Dapagliflozin Tablets, Adenosylcobalamin Capsules, and Mesobam Injection [1] - The total sales revenue for the selected products in 2024 is projected to be 405 million yuan [1]

Core Viewpoint - The company has announced significant changes in its governance structure, including the cancellation of the supervisory board and amendments to its articles of association, alongside updates on its financial performance and participation in national drug procurement programs [7][8][9][46]. Financial Performance - The company reported a 31.47% increase in revenue from the hygiene products segment compared to the same period last year, driven by rising demand for medical-grade sanitary napkins and increased promotional efforts [44]. - The company’s registered capital changed from RMB 42,399.7117 million to RMB 49,221.0016 million following the repurchase and cancellation of restricted stocks and the issuance of shares for asset acquisition [9][11]. Governance Changes - The supervisory board will be abolished, with its responsibilities transferred to the audit committee of the board of directors, in compliance with the revised Company Law and related regulations [8][9]. - Amendments to the articles of association include the removal of supervisory board provisions, updates on the responsibilities of the controlling shareholder, and the introduction of independent director sections [12][13][14]. Drug Procurement Participation - The company’s subsidiary, Hunan Qianjin Xiangjiang Pharmaceutical Co., Ltd., has participated in the national drug procurement process, with three products expected to be selected for the 11th batch of national drug centralized procurement [46]. - The procurement cycle for selected products will run until December 31, 2028, which could enhance the company's market presence and brand influence if contracts are signed and executed successfully [51].

Core Viewpoint - Qianjin Pharmaceutical (600479) announced that its subsidiary, Hunan Qianjin Xiangjiang Pharmaceutical Co., Ltd., participated in the 11th national centralized procurement organized by the National Organization for Drug Procurement Office, with three products expected to be selected for this procurement [1] Group 1 - Qianjin Xiangjiang Pharmaceutical is bidding for three products: Adenosylcobalamin Capsules, Fluvoxamine Tablets, and Dapoxetine Tablets [1]

Core Viewpoint - Qianjin Pharmaceutical announced that its subsidiary, Qianjin Xiangjiang Pharmaceutical, participated in the 11th batch of national centralized drug procurement, with three products expected to be selected for procurement [1] Group 1: Selected Products and Pricing - Adenosylcobalamin capsules are expected to be selected at a price of 4.88 yuan per box, primarily supplying Hunan, Guangxi, and Guizhou [1] - Fluvoxamine tablets are expected to be selected at a price of 7.14 yuan per box, primarily supplying Zhejiang, Fujian, and Chongqing [1] - Dopamine hydrazine tablets are expected to be selected at a price of 18.88 yuan per box, primarily supplying Sichuan, Hebei, Tianjin, and Ningxia [1] Group 2: Market and Sales Outlook - As of the end of Q3 2025, these products have not generated sales in the domestic market [1] - The procurement cycle for selected products will be from the execution date of the selection results until December 31, 2028 [1]

Core Viewpoint - The company announced that its subsidiary, Hangzhou Kang En Bei Pharmaceutical Co., Ltd., is set to participate in the national organized bulk procurement of pharmaceuticals, with its product, Adenosylcobalamin capsules, expected to win the bid in this round of procurement [1]. Group 1 - The company is involved in the national organized bulk procurement process, specifically the 11th batch [1]. - The product Adenosylcobalamin capsules has been selected based on market potential across various provinces [1]. - The official announcement of the bid results will be published by the Joint Procurement Office after the evaluation process [1].

Core Viewpoint - Kang En Bei (600572.SH) announced that its wholly-owned subsidiary, Hangzhou Kang En Bei Pharmaceutical Co., Ltd., participated in the 11th batch of national centralized drug procurement, with its product adenosylcobalamin capsules expected to win the bid [1] Group 1: Company Information - Hangzhou Kang En Bei's product adenosylcobalamin capsules is selected based on market potential across various provinces [1] - The results of the bidding will be officially announced after being published by the Joint Procurement Office [1]

Core Viewpoint - The announcement indicates that the company's subsidiary, Hangzhou Kang En Bei Pharmaceutical Co., Ltd., has participated in the national organized bulk procurement of pharmaceuticals, with a favorable outcome for its product, adenosylcobalamin capsules [1] Group 1: Procurement Details - Hangzhou Kang En Bei's adenosylcobalamin capsules are proposed to be awarded a bid at a price of 3.81 yuan per box [1] - The proposed supply quantity for the provinces (regions) is 8.3224 million capsules, with supply locations including Sichuan, Hubei, and Ningxia [1] - The procurement cycle is set for 3 years, with a contractual agreed supply volume of 2.62 million capsules [1] Group 2: Impact on Company Performance - The successful bid is expected to facilitate rapid sales growth and market expansion for the product [1] - This development is anticipated to have a positive impact on the company's future operating performance [1]

Core Viewpoint - North China Pharmaceutical has received the drug registration certificate for Adenosylcobalamin capsules (0.5mg) from the National Medical Products Administration, indicating a significant regulatory approval for the company’s product line [1] Group 1: Company Developments - The company announced the approval of Adenosylcobalamin capsules, which are primarily used for the prevention and treatment of Vitamin B12 deficiency [1] - The product is also indicated for supplementation when dietary intake of Vitamin B12 is insufficient and for treating megaloblastic anemia [1]

Core Viewpoint - North China Pharmaceutical (600812.SH) has received approval from the National Medical Products Administration for the registration certificate of Adenosylcobalamin capsules (0.5mg) [1] Group 1: Product Information - Adenosylcobalamin can inhibit abnormal fat synthesis in nerve myelin, blocking the occurrence and development of nerve fiber demyelination [1] - It promotes protein and lipid synthesis, repairing damaged nerves, and lowers abnormal TNFα levels, inhibiting the occurrence of SACD [1] - The product participates in the tricarboxylic acid cycle, promoting the metabolism of three major substances, and maintains normal cell function [1] Group 2: Medical Applications - Adenosylcobalamin is primarily used for the prevention and treatment of vitamin B12 deficiency, especially when dietary intake is insufficient due to conditions like consumptive diseases, hyperthyroidism, pregnancy, and lactation [1] - It is also indicated for megaloblastic anemia and other related conditions [1]